Medpace forecasts 2026 revenue between $2.805 bln and $2.885 bln.
Company expects 2026 GAAP net income of $494 mln to $514 mln.
Medpace projects 2026 diluted EPS of $17.25 to $17.95.
Overview
US clinical research firm's Q2 revenue rose 17% yr/yr, beating analyst expectations.
Q2 net income rose to $121 mln, with net income margin up to 17.2%.
Company repurchased 705,616 shares for $295 mln in Q2.
Result drivers
Backlog conversion - Co said Q2 revenue growth was driven by a backlog conversion rate of 24.1%.
New business awards - Net new business awards rose 28% yr/yr to $796 mln.
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$707.33 mln
$687.65 mln (11 Analysts)
Q2 Net Income
$121.36 mln
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell".
MEDP•
